Citation & Authors
Diabetes Res Clin Pract. 2025;226:112357.
ABSTRACT · RESEARCH SUMMARY
Research summary
This TriNetX target trial emulation compared SGLT2 inhibitors with nonuse, DPP-4 inhibitors, and GLP-1 drugs. Dialysis risk was lower in all three comparisons (HRs 0.657, 0.458, and 0.531, respectively). Acute kidney injury and death were also less frequent than among nonusers and DPP-4 inhibitor users. The study relies on medical records and matching methods and cannot directly replace randomized trials specifically in polycystic kidney disease.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
